# Program 03 Prostate Cancer

> **NIH NIH P30** · DANA-FARBER CANCER INST · 2024 · $40,622

## Abstract

Prostate Cancer Program
Project Summary / Abstract
The Prostate Cancer Program seeks to improve outcomes for all prostate cancer patients by bringing together
a multidisciplinary team of investigators across the DF/HCC consortium to catalyze and accelerate research
leading to clinical benefit. A founding premise of the Program is that genuine progress in the management of
prostate cancer requires iterative fundamental discovery through research in model systems and in patient-
derived samples, clinical translation, and subsequent analysis of patient-derived clinical samples to assess
mechanisms of action and sensitivity or resistance in vivo. The Program harnesses CCSG structures and
resources to achieve this iterative cycle. Additionally, the Program addresses the diversity of our catchment
area (Massachusetts) and pays particular attention to training the next generation of basic and clinical
investigators across the consortium.
The Program’s 66 members (42 primary and 24 secondary) represent seven DF/HCC institutions and 11
academic departments. In 2019, peer-reviewed grant funding attributed to the Program was $2.6 million in
direct costs from the NCI and $3.4 million from other sponsors. During the current funding period, primary
Program members published 840 cancer-relevant papers. Of these, 27% were inter-institutional, 30% were
intra-programmatic, and 31% were inter-programmatic collaborations between two or more DF/HCC members.
To achieve the Program mission, our Specific Aims for the next CCSG funding period are to 1) Improve
detection and early treatment of aggressive prostate cancer; 2) Identify mechanisms of resistance to
current therapies and identify further targetable vulnerabilities; and 3) Exploit tumor specific vulnerabilities
through biomarker driven clinical trials that include diverse patient populations. The disproportionate burden
of prostate cancer on African American men underlies key elements of each Aim, which therefore depend in
part on the Community Outreach and Engagement (COE) functions of the Cancer Center. In addition,
Program members rely heavily on Center collaborative and clinical trials structures and shared resources.

## Key facts

- **NIH application ID:** 10768660
- **Project number:** 5P30CA006516-59
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** Steven P. Balk
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $40,622
- **Award type:** 5
- **Project period:** 1997-03-10 → 2026-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10768660

## Citation

> US National Institutes of Health, RePORTER application 10768660, Program 03 Prostate Cancer (5P30CA006516-59). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10768660. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*